FMP

FMP

Enter

VNDA - Vanda Pharmaceutical...

photo-url-https://images.financialmodelingprep.com/symbol/VNDA.png

Vanda Pharmaceuticals Inc.

VNDA

NASDAQ

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

4.13 USD

0.05 (1.21%)

VNDA Financial Statements

Year

2024

2023

2022

2021

Total Revenue

198.77M

192.64M

254.38M

268.68M

Cost of Revenue

0

14.8M

24.28M

25.63M

Gross Profit

198.77M

177.84M

230.1M

243.05M

Operating Expenses

239.43M

191.8M

223.77M

200.89M

Research and Development

74.43M

76.82M

85.77M

75.36M

Selling, General & Administrative Expenses

146.41M

112.88M

136.49M

124.05M

Selling & Marketing Expenses

0

500k

2.6M

6.7M

General & Administrative Expenses

0

112.38M

133.88M

117.35M

Other Expenses

18.59M

2.09M

1.52M

1.48M

Operating Income

-40.66M

-13.95M

6.33M

42.16M

Total Other Income/Expenses Net

17.74M

20.29M

4.97M

199k

Income Before Tax

-22.92M

6.34M

11.3M

42.36M

Income Tax

-4.02M

3.83M

5.03M

9.21M

Net Income

-18.9M

2.51M

6.28M

33.15M

Basic EPS

-0.33

0.04

0.11

0.6

EPS Diluted

-0.33

0.04

0.11

0.58

Basic Average Shares

58.15M

57.38M

56.46M

55.55M

Diluted Average Shares

58.15M

57.56M

56.98M

56.92M

EBITDA

-40.66M

-10.94M

9.06M

45.01M

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

-155.39M

-157.9M

-164.18M

-197.33M

Net Income

-18.9M

2.51M

6.28M

33.15M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-174.29M

-155.39M

-157.9M

-164.18M

Other Distributions

-18.9M

2.51M

6.28M

33.15M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

12.68M

9.14M

10.97M

12.38M

Annual Depreciation

0

3.01M

2.73M

2.84M

Capital Expenditure

-490k

-383k

-679k

-552k

Net PPE

13.17M

6.51M

8.92M

10.1M

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep